Marshall Wace’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,217,044
| Closed | -$57.8M | – | 2920 |
|
|
2025
Q3 | $57.8M | Sell |
1,217,044
-201,171
| -14% | -$9.74M | 0.06% | 281 |
|
|
2025
Q2 | $75.7M | Sell |
1,418,215
-189,627
| -12% | -$8.62M | 0.09% | 221 |
|
|
2025
Q1 | $65.1M | Buy |
1,607,842
+1,332,768
| +485% | +$56.5M | 0.08% | 213 |
|
|
2024
Q4 | $7.65M | Buy |
+275,074
| New | +$8.33M | 0.01% | 895 |
|
|
2024
Q2 | – | Sell |
-120,674
| Closed | -$3.05M | – | 2502 |
|
|
2024
Q1 | $3.05M | Buy |
+120,674
| New | +$2.9M | ﹤0.01% | 1191 |
|
|
2023
Q4 | – | Sell |
-260,535
| Closed | -$13.2M | – | 2131 |
|
|
2023
Q3 | $13.2M | Sell |
260,535
-662,523
| -72% | -$30.8M | 0.03% | 557 |
|
|
2023
Q2 | $43.1M | Sell |
923,058
-158,667
| -15% | -$7.27M | 0.08% | 255 |
|
|
2023
Q1 | $41.4M | Sell |
1,081,725
-421,639
| -28% | -$18.8M | 0.09% | 256 |
|
|
2022
Q4 | $82.4M | Buy |
1,503,364
+752,524
| +100% | +$32.2M | 0.19% | 113 |
|
|
2022
Q3 | $25.6M | Sell |
750,840
-254,842
| -25% | -$3.9M | 0.06% | 377 |
|
|
2022
Q2 | $9.5M | Buy |
+1,005,682
| New | +$10.5M | 0.02% | 912 |
|
|
2022
Q1 | – | Sell |
-4,082
| Closed | -$86K | – | 3294 |
|
|
2021
Q4 | $86K | Buy |
+4,082
| New | +$90.5K | ﹤0.01% | 3415 |
|
|
2020
Q2 | – | Sell |
-4,664
| Closed | -$99K | – | 1505 |
|
|
2020
Q1 | $99K | Buy |
+4,664
| New | +$100K | ﹤0.01% | 1321 |
|
Other funds holding AKRO
Marshall Wace's AKRO Position: Q4 2025 in Review
Marshall Wace sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,217,044 shares — an estimated $57.8M sold.
Marshall Wace first reported a position in AKRO in Q1 2020 and held it in 13 quarters. The position peaked at $82.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Marshall Wace reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Marshall Wace sold 1,217,044 Akero Therapeutics shares in Q4 2025, an estimated $57.8M.
- Marshall Wace first reported a position in Akero Therapeutics in Q1 2020 and held it in 13 quarters.
- Marshall Wace's Akero Therapeutics position peaked at $82.4M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.